학술논문
Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial
Document Type
Article
Author
Matheron, Sophie; Descamps, Diane; Boué, François; Livrozet, Jean-Michel; Lafeuillade, Alain; Aquilina, Christian; Troisvallets, Didier; Goetschel, Agnès; Brun-Vezinet, Françoise; Mamet, Jean-Philippe; Thiaux, Cécile; Allegre, T; Bataille, P; Bazin, C; Bentata, M; Bergmann, JF; Beytout, J; Bicart-See, A; Bodard, L; Brottier-Mancini, E; Caron, F; Cassuto, JP; Chousterman, M; Counillon, E; Delfraissy, JF; Dellamonica, P; Doll, J; Faller, JP; Gallais, H; Garre, M; Gastaut, JA; Gilquin, J; Herson, S; Hoen, B; Jarousse, B.; Katlama, C; Lacoste, D; Lange, JM; Lecomte, I; Lepeu, G; Lucht, F; Malkin, JE; Massip, P; Mechali, D; Molina, JM; Mouton, Y; Pathe, JP; Peyramond, D; Philibert, P; Plaisance, N; Polomenie, P; Remy, G; Rispal, P; Roue, R; de Saint Martin, L; Sereni, D; Sicard, D; Sobel, A; Stahl, JP; Trepo, C; De Truchis, P; Vermersch, A; Welker, Y; Izopet, J; Vabret, A; Peytavin., G
Source
Antiviral Therapy; February 2003, Vol. 8 Issue: 2 p163-171, 9p
Subject
Language
ISSN
13596535
Abstract
Objective To compare the efficacy and safety of a triple nucleoside combination to a protease inhibitor-containing triple regimen as first-line antiretroviral therapy (ART) in HIV-1-infected patients.Design Open-label study in HIV-1-infected ART-naive adults, randomized to receive either Combivir® (lamivudine 150 mg/zidovudine 300 mg twice daily) + abacavir (300 mg twice daily), or Combivir® + nelfinavir (750 mg every 8 h) for 48 weeks. Plasma HIV-1 RNA, CD4 cell count and adverse events were assessed at baseline and weeks 4, 8, 16, 24, 32, 40 and 48.Results 195 subjects (131 men, 64 women), median age 34 years, were randomized: 98 received combivir/abacavir and 97 combivir/nelfinavir. Baseline median plasma HIV-1 RNA was 4.2 log10copies/ml [Interquartile range (IQR): 3.7-4.5.2] and 4.1 log10copies/ml (IQR: 3.8–4.6), respectively. Baseline median CD4 cell count was 387 cells/mm3(IQR: 194–501) and 449 cells/mm3(IQR: 334–605), respectively. Nine patients (3 vs 6, respectively) did not start treatment or did not have any available efficacy data. At week 48, using the intent to treat analysis (switch/missing equals failure), plasma HIV-1 RNA was <50 copies/ml in 54/95 (57%) and 53/91 (58%) of subjects, respectively. Median CD4 increase was +110 and +120 cells/mm3, respectively. Possible hypersensitivity reactions to abacavir were reported in four subjects (4%).Conclusion The triple nucleoside combination combivir/abacavir is well tolerated as a first-line ART regimen in HIV-1-infected adults, with comparable antiviral activity to a nelfinavir-containing regimen at week 48.